Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis

References

• Carson JL, Strom BL, Morse ML et al The relative gastrointestinal toxicity of the nonsteroidal anti inflammatory drugs. Arch. Intern. Med. 147,1054–1059 (1987).
   PubMed Web of Science ®Google Scholar
• Roth SH, Bennett RE. Nonsteroidal anti- inflammatory drug gastropathy. Recognition and response. Arch. Intern. Med. 147,2093–2100 (1987).
   PubMedGoogle Scholar
• Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann. Intern Med 114,257–263 (1991).
   Google Scholar
• Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J. Rheumatol 26\(Suppl. 56), 18–24 (1999).
   Google Scholar
• Flower RJ. Non-steroidal anti- inflammatory drugs: back to the future. Rheumatology (Oxford) 38,693–696 (1999).
   PubMedGoogle Scholar
• Beejay U, Wolfe MM. Cyclooxygenase-2 selective inhibitors: panacea or flash in the pan? Gastroentemlogy117, 1002–1005 (1999).
   PubMedGoogle Scholar
• Peterson WL, Cryer B. COX-1-sparing NSAIDs — is the enthusiasm justified? JA M4 282,1961-1963 (1999).
   Google Scholar
• Lipsky LP, Abramson SB, Crofford L, Dubois RN, Simon LS, van de Putte LB. The classification of cyclooxygenase inhibitors. J. Rheumatol 25,2298–2303 (1998).
   Google Scholar
• Hawkey CJ. COX-2 inhibitors. Lancet353, 307–314 (1999).
   PubMed Web of Science ®Google Scholar
• Brooks P, Emery P, Evans JF et al Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford) 38,779–788 (1999).
   PubMed Web of Science ®Google Scholar
• Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of gastrointestinal and platelet effects. Arthritis Rheum. 41,1591–1602 (1998).
   PubMed Web of Science ®Google Scholar
• Laine L, Harper S, Simon T et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastmenterology 117,776–783 (1999).
   Google Scholar
• Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAIVIA 282,1921–1928 (1999).
   PubMed Web of Science ®Google Scholar
• Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of gastrointestinal and platelet effects. Arthritis Rheum. 41,1591–1602 (1998).
   PubMed Web of Science ®Google Scholar
• Emery P, Zeidler H, Kvien TK et al. Randomised double-blind comparison of celecoxib versus diclofenac in long-term management of rheumatoid arthritis. Lancet354, 2106–2111 (1999).
   PubMed Web of Science ®Google Scholar
• Langman MJ, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAIVIA 282,1929–1933 (1999).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Silverstein FE, Agrawal NM et al Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am. J. Gastroenterol 95, 1681–1690 (2000).
   Google Scholar
• Silverstein FE, Faich G, Goldstein JL et al Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284,1247–1255 (2000).
   Google Scholar
• Hrachovec JB, Mora M. Reporting of 6- month vs. 12-month data in a clinical trial of celecoxib. JAIVIA 286,2398–2400 (2001).
   Google Scholar
• Bombardier C, Lame L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl. I Med343, 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Drug consumption in Norway 1997–2001 (in Norwegian: Legemiddelforbruket i Norge 1997–2001). Norsk Folkehelseinstitutt, Oslo, Norway, (2002).
   Google Scholar
• Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. PharmacoEconomics19 (Suppl. 1), 33–47 (2001).
   Google Scholar
• Chancellor JV, Hunsche E, de Cruz E, Sarasin FR Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. PharmacoEconomics 19 (Suppl. 1), 59–75 (2001).
   Google Scholar
• Zabinski RA, Burke TA, Johnson J et al An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. PharmacoEconomics 19\(Suppl. 1), 49–58 (2001).
   Google Scholar
• Haglund U, Svarvar P The Swedish ACM model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. keumatology (Oxford) 39\(Suppl. 2), 51–56 (2000).
   Google Scholar
• Svarvar F Aly A. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. keumatology Oxford)39(Suppl. 2), 43–50 (2000).
   Google Scholar
• Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA. Incremental cost-effectiveness analysis comparing rofecoxib with non-selective NSAIDs in osteoarthritis. PharmacoEconomics 19, 1039–1049 (2001).
   Google Scholar
• Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin. Ther. 23,1061–1079 (2001).
   Google Scholar
• Data 4.0 for Healthcare. User's manual. Treeage Software Inc., MA, USA (2001).
   Google Scholar
• Kristiansen IS, Kvien TK, Nord E. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis. Arthritis Rheum. 42,2293–2302 (1999).
   Google Scholar
• DRG Price List 2000 and Coding Guide (In Norwegian: Prisliste DRG 1999 med kodeveiledning). Ministry of Health and Social Affairs, Oslo, Norway (1999).
   Google Scholar
• Fee Schedule for Private Practitioners1999-2000 (in Norwegian). The Norwegian Medical Association, Oslo, Norway (1999).
   Google Scholar
• Fee Schedule for Out-patient Clinics in Public Hospitals as of 1 April 1999 (in Norwegian: Forskrifter og takster for offentlige poliklinikker fra 1.april 1999). Ministry of Health and Social Affairs, Oslo, Norway (1999).
   Google Scholar
• Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann. Intern Med 123, 241–249 (1995).
   PubMed Web of Science ®Google Scholar
• Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am. j Med 91(3), 213–222 (1991).
   PubMed Web of Science ®Google Scholar
• Fries JE Assessing and understanding patient risk. Scand j Rheumatol 92 (Suppl.), 21–24 (1992).
   Google Scholar
• Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut28, 527–532 (1987).
   PubMed Web of Science ®Google Scholar
• Mellem H, Stave R, Myren J et al. Symptoms in patients with peptic ulcer and hematemesis and/or melena related to the use of non-steroid anti-inflammatory drugs. Scam/. j Gashueriteml. 20,1246–1248 (1985).
   Google Scholar
• Choudari CP, Elton RA, Palmer KR. Age- related mortality in patients treated endoscopically for bleeding peptic ulcer. Gastmintest. Endosc. 41,557–560 (1995).
   Google Scholar
• Koness RJ, Cutitar M, Burchard KW Perforated peptic ulcer. Determinants of morbidity and mortality. Am. Surg 56, 280–284 (1990).
   Google Scholar
• Irvin TT. Mortality and perforated peptic ulcer: a case for risk stratification in elderly patients. Br. Surg 76,215–218 (1989).
   PubMed Web of Science ®Google Scholar
• Svanes C, Salvesen H, Stangeland L, Svanes K, Soreide 0. Perforated peptic ulcer over 56 years. Time trends in patients and disease characteristics. Gut 34,1666–1671 (1993).
   Google Scholar
• Wara P, Berg V, Amdrup E. Factors influencing mortality in patients with bleeding ulcer. Review of 7 years' experience preceding therapeutic endoscopy. Acta Chir. Scand 149,775–785 (1983).
   Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl. J. Med 340,1888–1899 (1999).
   PubMed Web of Science ®Google Scholar
• Kvien TK., Kaasa S, Smedstad LM. Performance of the Norwegian SF-36 health survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures. j Gun. Epidemiol 51(11), 1077–1086 (1998).
   Google Scholar
• Nord E. A table of values for cost- effectiveness analysis in healthcare (in Norwegian: Veiledende verditall for kostnad-nytte-analyser av helsetjenester). Tidsskr Nor Laegefomn 116,3246–3249 (1996).
   PubMedGoogle Scholar
• Nord E. Health status index models for use in resource allocation decisions. A critical review in the light of observed preferences for social choice. Int. J. Technol Assess. Healthcare 12,31–44 (1996).
   PubMedGoogle Scholar
• Nord E, Richardson J, Macarounas- Kirchmann K. Social evaluation of healthcare versus personal evaluation of health states: Evidence on the validity of four health state scaling instruments using Norwegian and Australian surveys. Int. J. Technol Assess. Healthcare 9,463–478 (1993).
   Google Scholar
• Ubel PA, Loewenstein PA, Scanlon D, Kamlet K. Individual utilities are inconsistent with rationing choices. Med Decis. Making 16,108–116 (1996).
   PubMed Web of Science ®Google Scholar
• Nord E. The person-trade-off approach to valuing healthcare programs. Med Decis. Making-15, 201–208 (1995).
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Hazevoet, HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. J. Rheumatol 11,158–161 (1984).
   Google Scholar
• Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JE Survival, prognosis and causes of death in rheumatoid arthritis. Arthritis Rheum. 29, 706–714 (1986).
   PubMed Web of Science ®Google Scholar
• Cobb S, Anderson F, Bauer W Length of life and cause of death in rheumatoid arthritis. N. Engl. Med 249,553–556 (1953).
   PubMed Web of Science ®Google Scholar
• Allebeck P, Ahlbom A, Allander E. Increased mortality among persons with rheumatoid arthritis but where RA does not appear on death certificate. Scand Rheumatol 10,301–306 (1981).
   Google Scholar
• Linos A, Worthington JW, O'Fallon WM, Kurland LT Epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence and mortality. Am. J. Epidemiol 111,87–98 (1980).
   PubMed Web of Science ®Google Scholar
• Population statistics. Deaths 1998 (in Norwegian). National Office of Statistics, Oslo, Norway (1999).
   Google Scholar
• Boers M. NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet357, 1222–1223 (2001).
   PubMedGoogle Scholar
• Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359,118–123 (2002).
   PubMed Web of Science ®Google Scholar
• Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104, 2280–2288 (2001).
   PubMed Web of Science ®Google Scholar
• White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am. j Cordial 89, 425–430 (2002).
   Google Scholar
• Physicians' Desk Reference 1999 (in Norwegian: Felleskatalog over farmasytiske spesialpraparater markedsfiCrt i Norge). Felleskatalogen Inc., Oslo, Norway (1999).
   Google Scholar
• Goldstein JL, Agrawal NM, Silverstein E Celecoxib and the incidence of clinically significant upper gastrintestinal events. Gastroenterology 116, A174 (2000).
   Google Scholar